Skip Navigation



JAC Advance Access published online on April 25, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg241
© 2003 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/6/1403    most recent
dkg241v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Griggs, D. J.
Right arrow Articles by Piddock, L. J. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Griggs, D. J.
Right arrow Articles by Piddock, L. J. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 The British Society for Antimicrobial Chemotherapy

Brief report

Selection of moxifloxacin-resistant Staphylococcus aureus compared with five other fluoroquinolones

Deborah J. Griggs 1, Herida Marona 1, Laura J. V. Piddock 1*

1 Antimicrobial Agents Research Group, Division of Immunity and Infection, The Medical School, University of Birmingham, Birmingham B15 2TT, UK

* Corresponding author. E-mail: l.j.v.piddock{at}bham.ac.uk.

Received 22 January 2003 ; revised 5 February 2003 ; accepted 7 March 2003

Abstract

Fluoroquinolone-resistant mutants were selected from Staphylococcus aureus NCTC 8532 (F77), and two GrlA mutants of F77 (F193 and F194) with moxifloxacin, sparfloxacin, ofloxacin, grepafloxacin, levofloxacin and trovafloxacin. For mutants selected from F77, moxifloxacin, grepafloxacin and sparfloxacin selected preferentially for mutations in gyrA (Glu-88->Lys). Ofloxacin and trovafloxacin selected most commonly for mutations in grlA, conferring substitutions for Ser-80. Three mutants of F77 were shown to have substitutions in both GrlA (Phe-80) and GyrA (Lys-88). Of the mutants selected from F193 (GrlA Phe-80), restriction fragment length polymorphism analysis of gyrA showed that 76/94 had a mutation at codon 84; those analysed in detail all had the substitution Ser->Leu. Two mutants selected with grepafloxacin contained the substitution Lys-88. One mutant selected with trovafloxacin contained a novel mutation in gyrA substituting Gly-82->Cys. Of the mutants selected from F194 (GrlA Tyr-80), 6/8 had a mutation in gyrA codon 84; of which three contained Leu. The MICs of most agents for mutants selected from F193 and F194 were similar, irrespective of the mutation selected. No mutants had any changes in grlB, and only one had a mutation in gyrB giving rise to the novel substitution Asp-437->His. The mutations arising in first-step mutants were influenced by the fluoroquinolone used for selection. The phenotypes and genotypes of second-step mutants, derived from mutants with existing mutations in grlA, were similar, regardless of the selecting antibiotic.

Keywords: fluoroquinolone, mutant selection, S. aureus
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
J. Cheng, J. A. Thanassi, C. L. Thoma, B. J. Bradbury, M. Deshpande, and M. J. Pucci
Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Heteroaryl Isothiazolones in Staphylococcus aureus
Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2445 - 2453.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. H. Grossman, D. J. Bartels, S. Mullin, C. H. Gross, J. D. Parsons, Y. Liao, A.-L. Grillot, D. Stamos, E. R. Olson, P. S. Charifson, et al.
Dual Targeting of GyrB and ParE by a Novel Aminobenzimidazole Class of Antibacterial Compounds
Antimicrob. Agents Chemother., February 1, 2007; 51(2): 657 - 666.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. S. Bhagwat, L. A. Mundkur, S. V. Gupte, M. V. Patel, and H. F. Khorakiwala
The Anti-Methicillin-Resistant Staphylococcus aureus Quinolone WCK 771 Has Potent Activity against Sequentially Selected Mutants, Has a Narrow Mutant Selection Window against Quinolone-Resistant Staphylococcus aureus, and Preferentially Targets DNA Gyrase
Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3568 - 3579.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
P. A. Wickman, J. A. Black, E. S. Moland, and K. S. Thomson
In Vitro Activities of DX-619 and Comparison Quinolones against Gram-Positive Cocci.
Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2255 - 2257.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. Pumbwe, L. P. Randall, M. J. Woodward, and L. J. V. Piddock
Evidence for Multiple-Antibiotic Resistance in Campylobacter jejuni Not Mediated by CmeB or CmeF
Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1289 - 1293.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
V. Ricci, M. L. Peterson, J. C. Rotschafer, H. Wexler, and L. J. V. Piddock
Role of Topoisomerase Mutations and Efflux in Fluoroquinolone Resistance of Bacteroides fragilis Clinical Isolates and Laboratory Mutants
Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1344 - 1346.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.